NCT01155063View on ClinicalTrials.gov

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

TerminatedOBSERVATIONAL
Enrollment

89

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Early Breast Cancer
Interventions
OTHER

Aromasin (exemestane)

Aromasin (exemestane), tablets 25 mg, once a day

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY